Therapeutic occupation of dopamine D2 antipsychotic receptors in Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 29, Issue 10, 2014, Pages 1096-

  Seeman, Philip ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; DOPAMINE 2 RECEPTOR; FALLYPRIDE F 18; FLUORINE 18; IOLOPRIDE I 123; MULTIDRUG RESISTANCE PROTEIN; RACLOPRIDE C 11; RADIOISOTOPE; SPIPERONE H 3; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; FALLYPRIDE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

AGGRESSION; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; DELUSION; DISSOCIATION CONSTANT; HALLUCINATION; HUMAN; LETTER; ANALOGS AND DERIVATIVES; BRAIN MAPPING; FEMALE; MALE; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PSYCHOTIC DISORDERS;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BRAIN MAPPING; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; SULPIRIDE;

EID: 84908612878     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4133     Document Type: Letter

References (5)

1. 18F] fallypride positron emission tomography. Int J Geriatric Psychiatry DOI: 10.1002/gps.4090
2. la Fougère C, Meisenzahl E, Schmitt G, et al. 2005. D2 receptor occupancy during high-And low-dose therapy with the atypical antipsychotic amisulpride: A 123I-iodobenzamide SPECT study. J NuclMed 46(6): 1028-1033.
3. Nyberg S, Nakashima Y, Nordström AL, et al. 1996. Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response. Br J Psychiatry 168 (suppl 29): 40-44.
4. Seeman P, 2011. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors. CNS Neurosci therap 17(2): 118-132
5. Seeman P, Van Tol HHM, 1995. Deriving the therapeutic concentrations for clozapine and haloperidol: The apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol-Mol Pharmacol Section 291: 59-66